- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT03598816
PolyImmune {Durvalumab (MEDI4736) and Tremelimumab} & Vaccine Orchestrated Treatment for Patients With Advanced/Metastatic Renal Cell Carcinoma (PIVOT-RCC)
A Randomized Phase II PIVOT-RCC (PolyImmune {Durvalumab (MEDI4736) and Tremelimumab} & Vaccine Orchestrated Treatment for Patients With Advanced/Metastatic Renal Cell Carcinoma) Trial
Studie Overzicht
Toestand
Conditie
Studietype
Fase
- Fase 2
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Diagnosis of histologically confirmed metastatic/advanced (inoperable) renal cell carcinoma with clear cell or non-clear cell histology.
- Measurable disease by RECIST 1.1
- Must have progressed on at least one but no more than two lines of targeted therapies or have increasing incidences and intolerability of ≥ Gr.2 AE (CTCAE) toxicity from ongoing targeted therapies. Targeted therapies that cause immediate toxicities and result in discontinuation of treatment within 4 weeks after the start of individual treatments are not considered as progression.
- Consented for genome sequencing and data sharing.
- Life expectancy of at least 12 weeks.
- At least 18 years of age.
- Karnofsky performance status ≥ 70%
Normal bone marrow and organ function as defined below:
- Absolute neutrophil count ≥ 1,000/mcL
- Platelets ≥ 75,000/mcL
- Hemoglobin ≥ 9.0 g/dL
- Serum bilirubin ≤ 1.5 x institutional upper limit of normal (IULN). This does not apply to patients with confirmed Gilbert's syndrome, who will be allowed in consultation with their physician
- AST(SGOT)/ALT(SGPT) ≤ 2.5 x IULN; for patients with hepatic metastases, ALT and AST ≤ 4 x IULN
- Measured creatinine clearance > 40 mL/min or calculated creatinine clearance > 40 mL/min as determined by Cockcroft-Gault using actual body weight
Evidence of post-menopausal status or negative urinary or serum pregnancy test for female pre-menopausal patients. Women will be considered post-menopausal if they have been amenorrheic for 12 months without an alternative medical cause. The following age-specific requirements apply:
- Women <50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and if they have luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution or underwent surgical sterilization (bilateral oophorectomy or hysterectomy).
- Women ≥50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments, had radiation-induced menopause with last menses >1 year ago, had chemotherapy-induced menopause with last menses >1 year ago, or underwent surgical sterilization (bilateral oophorectomy, bilateral salpingectomy or hysterectomy).
- Ability to understand and willingness to sign an IRB approved written informed consent document (or that of legally authorized representative, if applicable).
Exclusion Criteria:
- Received any immuno-oncology agents including, but not limited to, other anti CTLA-4, including tremelimumab anti-PD-1, anti-PD-L1 including durvalumab, and anti-programmed cell death ligand 2 (anti-PD-L2) antibodies, excluding therapeutic anticancer vaccines. Patients with prior adjuvant or neoadjuvant treatment of targeted therapies for RCC are eligible.
- A history of other malignancy ≤ 2 years previous with the exception of basal cell or squamous cell carcinoma of the skin which were treated with local resection only or carcinoma in situ of the cervix.
- Currently receiving any other investigational agents.
- Spinal cord compression or clinically active central nervous system metastasis, defined as untreated and symptomatic, or requiring therapy with corticosteroids. Subjects with treated brain metastasis that are no longer symptomatic may be included. A minimum of 2 weeks must have elapsed between the end of radiation and the study enrollment.
- A history of allergic reactions attributed to compounds of similar chemical or biologic composition to durvalumab, tremelimumab, vaccines, or other agents used in the study.
- Receipt of live attenuated vaccine within 30 days prior to the first dose of study treatment.
- Any unresolved toxicity NCI CTCAE Grade ≥2 from previous anticancer therapy with the exception of alopecia, vitiligo, and the laboratory values defined in the inclusion criteria -Patients with Grade ≥2 neuropathy will be evaluated on a case-by-case basis after consultation with the Study Physician.
- Patients with irreversible toxicity not reasonably expected to be exacerbated by treatment with durvalumab or tremelimumab may be included only after consultation with the Study Physician.
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, interstitial lung disease, or serious chronic gastrointestinal conditions associated with diarrhea.
- Mean QT interval corrected for heart rate using Fridericia's formula (QTcF) ≥470 ms calculated from 3 ECGs (within 15 minutes at 5 minutes apart).
- History of leptomeningeal carcinomatosis.
- History of syncopal or vasovagal episode as determined by medial record and history in the 6-month period prior to first vaccination administration.
- Individuals in whom a skinfold measurement of the cutaneous and subcutaneous tissue for eligible injection sites (left and right medial deltoid region) exceeds 40 mm.
- Individuals in whom the ability to observe possible local reactions at the eligible injection sites (deltoid region) is, in the opinion of the investigator, unacceptably obscured due to a physical condition or permanent body art.
- Therapeutic or traumatic metal implant in the skin or muscle of either deltoid region.
- Any current chronic or active neurologic disorder, including seizures and epilepsy, requires active medical management.
- Current use of any electronic stimulation device, such as cardiac demand pacemakers, automatic implantable cardiac defibrillator, nerve stimulators, or deep brain stimulators.
- Major surgical procedure (as defined by the PI) within 28 days prior to the first dose of durvalumab and tremelimumab. Note: Local surgery of isolated lesions for palliative intent is acceptable.
- History of allogenic organ transplantation.
Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease [eg, colitis or Crohn's disease], diverticulitis [with the exception of diverticulosis], systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome [granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc]). The following are exceptions to this criterion:
- Patients with vitiligo or alopecia
- Patients with hypothyroidism (eg, following Hashimoto syndrome) stable on hormone replacement
- Any chronic skin condition that does not require systemic therapy
- Patients without active disease in the last 5 years may be included but only after consultation with the study physician
- Patients with celiac disease controlled by diet alone
- History of active primary immunodeficiency
- Active infection including tuberculosis (clinical evaluation that includes clinical history, physical examination and radiographic findings, and tuberculosis testing in line with local practice), hepatitis B (known positive HBV surface antigen (HBsAg) result), hepatitis C, or human immunodeficiency virus (positive HIV 1/2 antibodies). Patients with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody [anti-HBc] and absence of HBsAg) are eligible. Patients positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA.
Current or prior use of immunosuppressive medication within 14 days before the first dose of durvalumab or tremelimumab. The following are exceptions to this criterion:
- Intranasal, inhaled, topical steroids, or local steroid injections (eg, intra articular injection)
- Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or its equivalent
- Steroids as premedication for hypersensitivity reactions (eg, CT scan premedication)
- Pregnant and/or breastfeeding. Women of childbearing potential must have a negative serum/urine pregnancy test within 14 days of study entry. All patients must be willing to employ effective birth control from screening to 90 days after the last dose of durvalumab monotherapy or 180 days after the last dose of durvalumab + tremelimumab combination therapy.
- Known HIV-positive status. These patients are ineligible because of the potential inability to generate an immune response to vaccines.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Experimenteel: Arm 1: Durvalumab + Tremelimumab + Neoantigen DNA Vaccine
|
-Durvalumab infusion will start approximately 1 hour (maximum 2 hours) after the end of the tremelimumab infusion
Andere namen:
-Tremelimumab will be administered first
-Integrated electroporation device
-At each vaccination time point, patients will receive two injections of the neoantigen DNA vaccine, one injection into each deltoid or lateralis.
-Baseline, C2D1, C3D1, C5D1, C7D1, and C9D1
|
Experimenteel: Arm 2: Durvalumab + Tremelimumab
|
-Durvalumab infusion will start approximately 1 hour (maximum 2 hours) after the end of the tremelimumab infusion
Andere namen:
-Tremelimumab will be administered first
-Baseline, C2D1, C3D1, C5D1, C7D1, and C9D1
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Safety of the combination of durvalumab & tremelimumab with or without neoantigen DNA vaccine when given to patients with renal cell carcinoma as measured by the percentage of patients with adverse events of grade 3 or higher
Tijdsspanne: Completion of cycle 1 (4 weeks)
|
|
Completion of cycle 1 (4 weeks)
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Response rate in patients with renal cell carcinoma treated with durvalumab and tremelimumab with or without neoantigen DNA vaccine by RECIST 1.1 as measured by percentage of patients with radiographic complete response or partial response
Tijdsspanne: Through completion of treatment (estimated to be 32-36 weeks)
|
|
Through completion of treatment (estimated to be 32-36 weeks)
|
Rate of progression-free survival (PFS) in patients with renal cell carcinoma treated with durvalumab and tremelimumab with or without neoantigen DNA vaccine
Tijdsspanne: Through 6 months after completion of treatment (estimated to be 15 months)
|
|
Through 6 months after completion of treatment (estimated to be 15 months)
|
Rate of overall survival (OS) in patients with renal cell carcinoma treated with durvalumab and tremelimumab with or without neoantigen DNA vaccine
Tijdsspanne: Through 6 months after completion of treatment (estimated to be 15 months)
|
-OS) defined as from time of randomization to time of death due to any cause and if patients are still alive at end of the study, to the time of last follow up
|
Through 6 months after completion of treatment (estimated to be 15 months)
|
Medewerkers en onderzoekers
Medewerkers
Onderzoekers
- Hoofdonderzoeker: James J Hsieh, M.D., Ph.D., Washington University School of Medicine
Publicaties en nuttige links
Studie record data
Bestudeer belangrijke data
Studie start (Verwacht)
Primaire voltooiing (Verwacht)
Studie voltooiing (Verwacht)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
- Neoplasmata per histologisch type
- Neoplasmata
- Urologische neoplasmata
- Urogenitale neoplasmata
- Neoplasmata per site
- Nier Ziekten
- Urologische ziekten
- Adenocarcinoom
- Neoplasmata, glandulair en epitheel
- Nierneoplasmata
- Carcinoom, niercel
- Carcinoom
- Antineoplastische middelen
- Antineoplastische middelen, immunologisch
- Durvalumab
- Tremelimumab
Andere studie-ID-nummers
- 202003083
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
product vervaardigd in en geëxporteerd uit de V.S.
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Niercelcarcinoom
-
Peking University People's HospitalOnbekendNatural Killer Cell-gemedieerde immuniteitChina
-
Postgraduate Institute of Medical Education and...VoltooidType 1 HEPATO RENAL SYNDROOM (HRS)Indië
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI); NovartisActief, niet wervendRefractaire Hurthle Cell-schildklierkankerVerenigde Staten
-
Hospices Civils de LyonWervingKwaadaardige tumoren als Chordoma, Adenoid Cystic Carcinoma en SarcoomFrankrijk
-
Hadassah Medical OrganizationOnbekendNatural Killer Cell-deficiëntie, familiaal geïsoleerdIsraël
-
Bristol-Myers SquibbVoltooidTrombose | Nierfunctiestoornis | Factor XI | ESRD (End-Stage Renal Disease)Verenigde Staten
-
Assistance Publique - Hôpitaux de ParisNog niet aan het werven
-
Bing HanVoltooidPure Red Cell Aplasia, verworvenChina
-
National Institute of Diabetes and Digestive and...WervingSchildklierkanker | Papillaire schildklierkanker | Hurthle Cell-schildklierkanker | Tall Cell Variant Schildklierkanker | Folliculaire schildklierkankerVerenigde Staten
-
Peking University First HospitalWervingNiercelcarcinoom, Clear Cell, SomatischChina
Klinische onderzoeken op Durvalumab
-
MedImmune LLCVoltooidStadium III Niet-kleincellige longkanker | OnherstelbaarVerenigde Staten, Canada, Italië, Spanje, Frankrijk, Hongkong, Portugal, Taiwan, Polen
-
Yonsei UniversityWervingPotentieel reseceerbaar stadium II/IIIa NSCLCKorea, republiek van
-
AstraZenecaKappa SantéActief, niet wervend
-
Academic Thoracic Oncology Medical Investigators...AstraZenecaVoltooidNiet-kleincellige longkanker NSCLCVerenigde Staten
-
Yonsei UniversityVoltooidSarcoomKorea, republiek van
-
NSABP Foundation IncVoltooidRectale kankerVerenigde Staten
-
Grupo Espanol Multidisciplinario del Cancer DigestivoAstraZeneca; Vall d'Hebron Institute of Oncology (VHIO)Werving
-
Institut Cancerologie de l'OuestAstraZenecaActief, niet wervendBotmetastasen | Prostaatkankerpatiënten | Knooppunt; ProstaatFrankrijk
-
AstraZenecaVoltooidGeavanceerde maligniteitChina